Feasibility of cognitive sparing approaches in children with intracranial tumors requiring partial brain radiotherapy: A dosimetric study using tomotherapy

James C Marsh1*, Rohit Godbole2, Aidnag Diaz3, Arnold Herskovic4 and Julius Turian5

Abstract

Background: To assess feasibility of sparing the neural stem cell compartment (NSC), hippocampus, and limbic circuit during partial brain radiotherapy (PBRT) for pediatric intracranial tumors.

Methods: Treatment plans were generated for the following pediatric intracranial tumors: low and high grade gliomas, low grade brainstem glioma, optic nerve glioma, hypothalamic glioma, skull base sarcoma, central nervous system (CNS) germinoma (involved field radiotherapy [IFRT] and whole ventricular radiotherapy [WVRT]), and craniopharyngioma. For each pathology, standard intensity-modulated radiotherapy (IMRT) plans were generated using helical tomotherapy, as well as IMRT plans which spared limbic circuit, hippocampus, and NSC. Biologically equivalent dose for late effects (BEDlate effects) was generated for limbic circuit, hippocampus, and NSC. Percent reduction in mean, maximum, and minimum physical dose and BED was calculated between plans.

Results: We reduced mean physical dose and BEDlate effects to these critical structures by 44% and 47.9% respectively (range 5.4-78.8% and 7-80.3%). Greatest benefits in relative dose reduction were seen in high grade hemispheric glioma cases; least relative dose reduction was seen in WVRT cases. Dosimetric coverage of treatment target (PTV) was equivalent in all cases as assessed by D95 and V100 metrics. Integral dose to uninvolved brain was reduced by mean of 7.6% (range -19.3% to +0.3%) in sparing plans.

Discussion and Conclusions: It is possible to spare limbic circuit, NSC, and hippocampus during PBRT for primary pediatric intracranial tumors using helical tomotherapy. This approach reduces integral dose delivered to uninvolved normal brain and may reduce late cognitive sequelae of cranial radiotherapy.

Keywords: Radiotherapy, pediatric brain tumor, cognitive preservation, neural stem cell, hippocampus, limbic circuit.
the maximum and mean doses to these same structures for each patient, an appropriate treatment target (PTV: planning target volume) was contoured, and this PTV was applied both the STD and SPA plans. The PTV varied by diagnosis, but generally consisted of the gross tumor as identified on imaging, areas of edema or areas otherwise felt to be at risk for containing microscopic tumor (for example, the ventricular system plus a 1cm margin for CNS germinoma whole ventricular radiotherapy plans), and an additional margin for setup uncertainty on the treatment table.

Adequate target coverage, as defined by the D95 (isodose line covering 95% of the PTV) and V100 (percent volume of the PTV receiving at least full dose/100% of the planned treatment dose), was required as the primary treatment objective in all plans (STD and SPA). The dose prescriptions/ treatment schedules for each plan type are shown in (Table 1). Also, standard constraints were applied to the following critical normal structures (OAR: organs at risk) in all plans (STD and SPA): right and left lenses, right and left eyes, right and left optic nerves, optic chiasm, pituitary/infundibulum/ hypothalamus, right and left cochleae, brainstem, and spinal cord. These standard OAR dose constraints are shown in (Table 2). For the SPA plans, we provided additional optimization criteria to maximally spare the study OAR (LC, HIP, and NSC) by placing restrictions on the mean and maximum doses to these structures (third priority). These study OAR were spared contralaterally for the supratentorial hemispheric low and high grade glioma and skull base sarcoma plans, and bilaterally for the other plans.

For each plan the physical doses and biological equivalent doses (BED) delivered to the following structures were calculated: PTV (D95, V100, minimum dose, and maximum dose) and study OAR (LC, HIP, and NSC: meandose, maximum dose, and minimum dose). Within each tumor subgroup, delivered physical dose and BED to the PTV and study OAR were compared between the STD and SPA plans, and percent relative differences were calculated. The physical doses delivered to the standard OAR (right and left lenses, right and left eyes, right and left optic nerves, optic chiasm, pituitary/infundibulum/

hypothalamus, right and left cochlea, brainstem, and spinal cord) were evaluated for each plan (STD and SPA) to ensure that they did not exceed our acceptance criteria (Table 2), but BED were not calculated and the dose delivered to these structures were not compared between the STD and SPA plans.

The BED, which represents a measure of the biologic likelihood of a given dose of radiation delivered on a given treatment schedule causing a given effect on a given tissue type (tumor or normal structure) for each of these structures was calculated using the following equation, where n is the number of fractions and d is the dose per fraction in Gy:

\[ \text{BED} = n \left( \frac{d}{(\alpha/\beta)_{	ext{tissue}}} \right) \]

We assumed an alpha/beta (α/β) ratio of 2 for late effects involving LC and HIP. For PTV and NSC we conservatively assumed an α/β ratio of 10 because it is a value previously demonstrated for other tumors and stem cell populations [22]. The α/β ratio represents the ability of a given cellular type to repair sublethal damage to its DNA generated by radiation exposure, and is generally low (around 2-3) for tissues with little or no cellular turnover (and thus plenty of time available to repair damage before the next mitosis) such as muscle cells, fibroblasts, and neurons. The α/β ratio is high (around 10) for cells which are proliferating quickly and thus have little time available for DNA repair between mitoses, such as skin, gut epithelial cells, stem cell populations, and most tumors. No such studies have been completed for human NSC in vivo, and therefore our choice of an α/β ratio of 10 for this cellular population remains speculative.

Since this is a dosimetric comparison study we investigated whether the SPA plans increase the integral dose to the normal uninvolved brain versus the STD plans. Integral dose, expressed in joules (J), represents the total energy deposited in a given mass of tissue, and is generally represented by multiplying the delivered dose (in Gray, or joules/kg of tissue) by the mass of tissue exposed (in kg). For each plan, OAR's designated as “uninvolved brain” which

| Tumor                              | Phase 1            | Phase 2            | Total Dose          |
|------------------------------------|--------------------|--------------------|--------------------|
| Hemispheric glioma, high grade     | 46Gy (23 fractions)| 14Gy (7 fractions) | 60Gy (30 fractions) |
| Hemispheric glioma, low grade      | 54Gy (30 fractions)| -                  | 54Gy (30 fractions) |
| Brainstem glioma, low grade        | 54Gy (30 fractions)| -                  | 54Gy (30 fractions) |
| Optic nerve glioma                 | 50.4Gy (28 fractions)| -                  | 50.4Gy (28 fractions)|
| Hypothalamic glioma                | 54Gy (30 fractions)| -                  | 54Gy (30 fractions) |
| Ependymoma                         | 54Gy (30 fractions)| -                  | 54Gy (30 fractions) |
| Craniopharyngioma                  | 54Gy (30 fractions)| -                  | 54Gy (30 fractions) |
| Skull-based sarcoma                | 60Gy (30 fractions)| -                  | 60Gy (30 fractions) |
| WVRT CNS germinoma                 | 30Gy (15 fractions)| 10Gy (5 fractions) | 40Gy (20 fractions) |
| IFRT CNS germinoma                 | 45Gy (25 fractions)| -                  | 45Gy (25 fractions) |
Table 2. Standard OAR dose constraints

Tumor

| OARs | Dose constraints for Std and Spa plans (PHASE 1) | Dose constraints for Std and Spa plans (PHASE 2) |
|------|--------------------------------------------------|--------------------------------------------------|
| Eyes | 0% to receive 30Gy | 0% to receive 5Gy |
| Lenses | 0% to receive 4Gy | 0% to receive 1Gy |
| Optic nerves | 0% to receive 41Gy | 0% to receive 11Gy |
| Optic chiasms | 0% to receive 41Gy | 0% to receive 11Gy |
| Brainstem | 0% to receive 41Gy | 0% to receive 11Gy |
| Cochleae | 0% to receive 18Gy | 0% to receive 2Gy |
| Hypothal/Pituitary | 0% to receive 15Gy | 0% to receive 3Gy |

High grade glioma, skull-based sarcoma

Low grade glioma, brainstem glioma, optic nerve gliomas, craniopharyngioma, hypothalamic glioma, ependymoma, WVRT CNS germinoma, IFRT CNS germinoma

Results

Dosimetric coverage of the treatment target (PTV) was excellent in all STD and SPA plans, with 94.8-96% of PTV receiving full dose in STD plans and 4.9-95% receiving full dose in SPA plans. However, there was greater dose inhomogeneity noted in the SPA plans, with minimum doses 56 to 99% (mean 90%) and maximum doses 101 to 128% (mean 109%) of prescription dose. The corresponding ranges for the STD plans were to 81 to 99% (mean 92%) minimum doses and 101 to 120% (mean 105%) maximum doses relative to the prescription dose. All plans (STD and SPA) were able to meet the dose constraints for all standards OAR as described in (Table 2) (individual plan data not shown).

SPA plans were able to significantly reduce mean physical dose and BED delivered to the study OAR (LC, HIP, and NSC) in all cases: percent reduction in mean physical dose 5.4 to 78.8 (mean 44) and percent reduction in mean BED 7 to 81.5 (mean 47.9). The corresponding percent reduction in mean physical dose and BED for the limbic circuit, hippocampus, and neural stem cell compartment were 5.4 to 77.8 (mean 43.3) and 7 to 80.3 (mean 47.2), 18.2 to 67.4 (mean 46.5) and 25.4 to 81.5 (mean 52.4), and 6.8 to 60 (mean 42.1) and 7.8 to 66.1 (mean 44.1), respectively. In most cases the minimum and maximum physical doses and BED delivered to the study OAR were also reduced in the SPA, although in some cases the minimum physical dose and BED were higher (craniopharyngioma and optic nerve glioma plans: LC absolute minimum physical dose increased by .05 to .1 Gy, mean 0.8 Gy) while in others the maximum physical dose and BED were higher (IFRT, WVRT, high grade glioma, low grade glioma, and craniopharyngioma plans: absolute maximum physical dose increased by .63 to 8.6 Gy, mean 2.5 Gy) for
Table 3A: Dosimetric Data

| Plan Type        | Structure          | Parameter | Std Physical Dose | Std BED | Sparing Physical Dose | Sparing BED | % Change Physical Dose | % Change BED |
|------------------|--------------------|-----------|-------------------|--------|-----------------------|------------|------------------------|--------------|
| **Low Grade Glioma** | PTV                | D95       | 50.40             | 59.5   | 50.40                 | 59.5       | 0                      | 0            |
|                  |                    | %V100     | 95.00             | N/A    | 95.00                 | N/A        | N/A                    | N/A          |
|                  |                    | Min Dose  | 45.25             | 52.6   | 41.20                 | 47.3       | -9                     | -10.1        |
|                  |                    | Max Dose  | 54.47             | 65.1   | 56.20                 | 67.5       | 3.2                    | 3.7          |
|                  | Contra NSC         | Mean Dose | 23.16             | 25.1   | 12.93                 | 13.5       | -44.2                  | -46.2        |
|                  |                    | Min Dose  | 5.70              | 5.82   | 2.52                  | 2.54       | -55.8                  | -56.4        |
|                  |                    | Max Dose  | 54.38             | 64.9   | 55.10                 | 65.9       | 1.3                    | 1.5          |
|                  | Contra Hippocampus | Mean Dose | 27.24             | 40.5   | 13.41                 | 16.6       | -50.8                  | -59          |
|                  |                    | Min Dose  | 19.10             | 25.6   | 7.26                  | 8.2        | -62                    | -68          |
|                  |                    | Max Dose  | 53.08             | 103.4  | 50.22                 | 95.2       | -5.4                   | -7.9         |
|                  | Contra Limbic      | Mean Dose | 17.00             | 22.2   | 8.67                  | 10         | -49                    | -54.9        |
|                  |                    | Min Dose  | 1.63              | 1.68   | 1.09                  | 1.11       | -33.1                  | -33.9        |
|                  |                    | Max Dose  | 54.38             | 107.2  | 55.73                 | 111.2      | 2.5                    | 3.7          |
| **Brainstem glioma** | PTV                | D95       | 54.0              | 63.7   | 54.0                  | 63.7       | 0                      | 0            |
|                  |                    | %V100     | 95.1              | N/A    | 95.0                  | N/A        | N/A                    | N/A          |
|                  |                    | Min Dose  | 43.6              | 49.9   | 41.7                  | 47.5       | -4.4                   | -4.8         |
|                  |                    | Max Dose  | 55.5              | 65.8   | 58.1                  | 69.4       | 4.7                    | 5.4          |
|                  | Bilateral NSC      | Mean Dose | 14.2              | 14.9   | 7.1                   | 7.3        | -50                    | -51.2        |
|                  |                    | Min Dose  | 0.9               | 0.9    | 0.8                   | 0.8        | -11.1                  | -11.1        |
|                  |                    | Max Dose  | 54.5              | 64.4   | 14.6                  | 15.3       | -73.2                  | -76.2        |
|                  | Bilateral Hippocampus | Mean Dose | 55.6              | 107.1  | 39.5                  | 65.5       | -29                    | -38.8        |
|                  |                    | Min Dose  | 53.4              | 100.9  | 16.6                  | 21.2       | -68.9                  | -79          |
|                  |                    | Max Dose  | 57.2              | 111.7  | 55.5                  | 106.8      | -3                     | -4.4         |
|                  | Bilateral Limbic   | Mean Dose | 5.2               | 5.7    | 1.1                   | 1.1        | -78.8                  | -80.3        |
|                  |                    | Min Dose  | 0.8               | 0.8    | 0.7                   | 0.7        | -12.5                  | -12.5        |
|                  |                    | Max Dose  | 54.5              | 104    | 3.6                   | 3.8        | -93.4                  | -96.3        |
Table 3B: Dosimetric Data

| Plan Type          | Structure | Parameter | Std Physical Dose | Std BED | Sparing Physical Dose | Sparing BED | % Change Physical Dose | % Change BED |
|--------------------|-----------|-----------|-------------------|--------|-----------------------|------------|------------------------|--------------|
| Optic nerve glioma | PTV       | D95       | 54                | 63.7   | 54                    | 63.7       | 0                      | 0            |
|                    |           |           |                   |        |                       |            |                        |              |
|                    |           |           | %V100             | N/A    | 53.5                  | N/A        | N/A                    | N/A          |
|                    |           | Min Dose  | 47.75             | 55.4   | 53.53                 | 62.8       | 12.1                   | 13.4         |
|                    |           | Max Dose  | 59.26             | 71     | 54.53                 | 64.4       | -8                     | -9.2         |
|                    |           | Bilateral NSC Mean Dose | 7.62 | 8.6 | 7.01 | 7.2 | -8.1 | -16.3 |
|                    |           | Min Dose  | 6.86              | 7      | 6.34                  | 6.5        | -7.5                   | -7.6         |
|                    |           | Max Dose  | 8.74              | 9      | 8.43                  | 8.7        | -3.5                   | -3.7         |
|                    |           | Bilateral Hippocampus Mean Dose | 5.1 | 5.5 | 3 | 3.2 | -41.2 | -41.8 |
|                    |           | Min Dose  | 0                 | 0      | 0.2                   | 0.2        | 100*                   | 100*         |
|                    |           | Max Dose  | 15.5              | 19.5   | 11.2                  | 13.3       | -27.7                  | -31.8        |
|                    |           | Bilateral Limbic Mean Dose | 0.56 | 0.57 | 0.53 | 0.53 | -5.4 | -7 |
|                    |           | Min Dose  | 0                 | 0      | 0.1                   | 0.1        | 100*                   | 100*         |
|                    | Skull based sarcoma | Max Dose | 15.18 | 19 | 7.82 | 8.8 | -48.5 | -53.5 |
|                    | PTV       | D95       | 59.3              | 71     | 59.5                  | 71.3       | 0                      | 0            |
|                    |           | %V100     | 94.8              | N/A    | 95                    | N/A        | N/A                    | N/A          |
|                    |           | Min Dose  | 48.09             | 55.8   | 45.46                 | 52.3       | -5.5                   | -6.2         |
|                    | Contra NSC Mean Dose | Max Dose | 15.5 | 19.5 | 11.2 | 13.3 | -27.7 | -31.8 |
|                    | Contra Hip-  | Min Dose  | 0.8               | 0.8    | 0.71                  | 0.7        | -12.5                  | -12.5        |
|                    | pocampus  | Max Dose  | 58.3              | 68.6   | 33.74                 | 37.2       | -42.1                  | -45.8        |
|                    | Mean Dose  | 18.2            | 23.2              | 13.8   | 16.7                  | -24.2      | -28                    |              |
|                    | Min Dose  | 9.8              | 11.3              | 9.2    | 10.5                  | -6.1       | -7.1                   |              |
|                    | Max Dose  | 25.8             | 35.9              | 18.1   | 23.1                  | -29.8      | -35.7                  |              |
|                    | Contra Limbic Mean Dose | Max Dose | 54.1 | 98.4 | 34.9 | 53.4 | -35.5 | -45.7 |
## Table 3C: Dosimetric Data

| Plan Type                | Structure    | Parameter | Std Physical Dose | Std BED  | Sparing Physical Dose | Sparing BED | % Change Physical Dose | % Change BED |
|--------------------------|--------------|-----------|-------------------|----------|-----------------------|------------|------------------------|--------------|
|                          |              |           |                   |          |                       |            |                        |              |
| **Craniopharyngioma**    | PTV          | D95       | 53.9              | 63.6     | 53.9                  | 63.6       | 0                      | 0            |
|                          |              | %V100     | 95                | N/A      | 95                    | N/A        | N/A                    | N/A          |
|                          |              | Min Dose  | 44.68             | 51.3     | 37.8                  | 42.6       | -15.4                  | -17          |
|                          |              | Max Dose  | 57.24             | 68.2     | 58.43                 | 69.8       | 2.1                    | 2.4          |
| Bilateral NSC            | Mean Dose    | 11.5      | 11.9              | 5.75     | 5.86                  | -50        | -50.8                  | -50.8        |
|                          | Min Dose     | 0.79      | 0.79              | 0.74     | 0.74                  | -6.1       | -6.1                   | -6.1         |
|                          | Max Dose     | 56.38     | 67                | 54.75    | 64.7                  | -2.9       | -3.4                   | -3.4         |
| Bilateral Hippocampus    | Mean Dose    | 10.44     | 12.3              | 7.55     | 8.5                   | -27.7      | -30.9                  |              |
|                          | Min Dose     | 8.51      | 9.7               | 4.97     | 5.4                   | -41.5      | -44.5                  |              |
|                          | Max Dose     | 48.6      | 88                | 43.89    | 76                    | -9.7       | -13.6                  |              |
| Bilateral Limbic         | Mean Dose    | 6.64      | 7.4               | 1.48     | 1.5                   | -77.7      | -79.5                  |              |
|                          | Min Dose     | 0.62      | 0.63              | 0.67     | 0.68                  | 8.1        | 7.5                    |              |
|                          | Max Dose     | 56.99     | 111.1             | 57.62    | 113                   | 1.1        | 1.7                    |              |
| **Hypothalamic glioma**  | PTV          | D95       | 53.80             | 63.4     | 53.9                  | 63.6       | 0.2                    | 0.3          |
|                          |              | %V100     | 94.80             | N/A      | 95                    | N/A        | N/A                    | N/A          |
|                          |              | Min Dose  | 53.65             | 63.2     | 49.39                 | 57.5       | -7.9                   | -8.9         |
|                          |              | Max Dose  | 54.51             | 64.4     | 60.22                 | 72.3       | 10.5                   | 12           |
| Bilateral NSC            | Mean Dose    | 8.49      | 8.7               | 3.4      | 3.4                   | -60        | -60.5                  |              |
|                          | Min Dose     | 0.68      | 0.68              | 0.52     | 0.52                  | -23.4      | -23.4                  |              |
|                          | Max Dose     | 35.66     | 39.9              | 16.07    | 16.9                  | -54.9      | -57.6                  |              |
| Bilateral Hippocampus    | Mean Dose    | 17.39     | 22.4              | 7.16     | 8                     | -58.8      | -64.2                  |              |
|                          | Min Dose     | 9.35      | 10.8              | 3.13     | 3.3                   | -66.5      | -69.5                  |              |
|                          | Max Dose     | 38.10     | 62.3              | 21.73    | 29.6                  | -43        | -52.4                  |              |
| Bilateral Limbic         | Mean Dose    | 4.90      | 5.3               | 2.59     | 2.7                   | -47.1      | -49                    |              |
|                          | Min Dose     | 0.39      | 0.39              | 0.38     | 0.38                  | -2.6       | -2.6                   |              |
|                          | Max Dose     | 54.41     | 103.8             | 51.42    | 95.5                  | -5.5       | -8                     |              |
## Table 3D: Dosimetric Data

| Plan Type | Structure | Parameter | Std Physical Dose | Std BED | Sparing Physical Dose | Sparing BED | % Change Physical Dose | % Change BED |
|-----------|-----------|-----------|-------------------|---------|-----------------------|------------|------------------------|-------------|
| IFRT CNS | PTV D95   |           | 44.8              | 52.8    | 45                    | 53.1       | 0.4                    | 0.5         |
|           | %V100     |           | 95                | N/A     | 95                    | N/A        | N/A                    | N/A         |
|           | Min Dose  |           | 44.28             | 52.1    | 25.15                 | 27.7       | -43.2                  | -46.9       |
|           | Max Dose  |           | 45.95             | 54.4    | 51.62                 | 62.3       | 12.3                   | 14.5        |
|           | Bilateral NSC | Mean Dose | 22.91            | 25      | 11.18                 | 11.7       | -51.2                  | -53.3       |
|           | Min Dose  |           | 9.28              | 9.6     | 2.85                  | 2.9        | -69.3                  | -70         |
|           | Max Dose  |           | 45.62             | 53.9    | 50.75                 | 61.1       | 11.2                   | 13.2        |
|           | Bilateral Hippocampus | Mean Dose | 33.37            | 55.6    | 9.18                  | 10.86      | -72.5                  | -80.5       |
|           | Min Dose  |           | 22.12             | 31.9    | 4.93                  | 5.4        | -77.7                  | -83         |
|           | Max Dose  |           | 44.96             | 85.4    | 33.5                  | 55.9       | -25.5                  | -34.5       |
|           | Bilateral Limbic | Mean Dose | 27.65            | 42.9    | 13                    | 16.4       | -53                    | -61.8       |
|           | Min Dose  |           | 14.6              | 18.9    | 3.9                   | 4.2        | -73.3                  | -77.8       |
|           | Max Dose  |           | 45.72             | 87.5    | 54.3                  | 113.3      | 18.8                   | 29.5        |
| Ependymoma | PTV D95  |           | 59.3              | 70      | 59.3                  | 70         | 0                      | 0           |
|           | %V100     |           | 51.8              | N/A     | 50.6                  | N/A        | N/A                    | N/A         |
|           | Min Dose  |           | 51.89             | 60      | 50.67                 | 58.5       | -2.4                   | -2.6        |
|           | Max Dose  |           | 61.36             | 72.7    | 65.09                 | 77.9       | 6.1                    | 7.2         |
|           | Bilateral NSC | Mean Dose | 9.42             | 9.68    | 3.86                  | 3.87       | -59                    | -60         |
|           | Min Dose  |           | 0.67              | 0.67    | 0.55                  | 0.55       | -17.8                  | -17.8       |
|           | Max Dose  |           | 40.88             | 45.9    | 20.49                 | 21.8       | -49.9                  | -52.6       |
|           | Bilateral Hippocampus | Mean Dose | 25.16            | 34.8    | 8.2                   | 9.2        | -67.4                  | -73.5       |
|           | Min Dose  |           | 11.46             | 13.4    | 2.73                  | 2.8        | -76.2                  | -78.8       |
|           | Max Dose  |           | 55.12             | 101.2   | 33.19                 | 49.9       | -39.8                  | -50.7       |
|           | Bilateral Limbic | Mean Dose | 3.34             | 3.5     | 2.16                  | 2.2        | -35.3                  | -36.3       |
|           | Min Dose  |           | 0.46              | 0.46    | 0.4                   | 0.4        | -13                    | -13         |
|           | Max Dose  |           | 33.43             | 50.4    | 19.07                 | 24.6       | -43                    | -51.2       |
### Table 3E: Dosimetric Data

| Plan Type       | Structure | Parameter | Std Physical Dose | Std BED | Sparing Physical Dose | Sparing BED | % Change Physical Dose | % Change BED |
|-----------------|-----------|-----------|-------------------|--------|-----------------------|------------|------------------------|--------------|
| **High grade glioma** | PTV46     | %V100     | 96                | N/A    | 95                    | N/A        | N/A                    | N/A          |
|                 |           | Min Dose  | 43.3              | 51.1   | 35.3                  | 40.7       | -18.5                  | -20.4        |
|                 |           | Max Dose  | 47.4              | 57.2   | 48.9                  | 59.3       | 3.2                    | 3.7          |
|                 | PTV60     | %V100     | 94.8              | N/A    | 95                    | N/A        | N/A                    | N/A          |
|                 |           | Min Dose  | 58.5              | 69.9   | 56.7                  | 67.4       | -3.1                   | -3.6         |
|                 |           | Max Dose  | 60.5              | 72.7   | 60.9                  | 73.3       | 0.7                    | 0.8          |
|                 | Contra NSC| Mean Dose | 33.6              | 37.4   | 12.2                  | 12.7       | -63.7                  | -66.1        |
|                 |           | Min Dose  | 19.6              | 20.9   | 2.6                   | 2.6        | -86.7                  | -87.5        |
|                 |           | Max Dose  | 60.5              | 72.7   | 51.3                  | 60.1       | -15.2                  | -17.4        |
|                 | Contra Hippocampus | Mean Dose | 33.3              | 51.8   | 8.4                   | 9.6        | -74.8                  | -81.5        |
|                 |           | Min Dose  | 24                | 33.6   | 3.3                   | 3.5        | -86.3                  | -89.6        |
|                 |           | Max Dose  | 53                | 99.8   | 26.1                  | 37.4       | -50.8                  | -62.5        |
|                 | Contra Limbic | Mean Dose | 44.6              | 77.8   | 24.6                  | 34.7       | -44.8                  | -55.4        |
|                 |           | Min Dose  | 23.3              | 32.3   | 3.5                   | 3.7        | -85                    | -88.5        |
|                 |           | Max Dose  | 60.5              | 72.7   | 51.3                  | 60.1       | -15.2                  | -17.4        |
| **WVRT CNS germi-noma** | PTV46     | %V100     | 95                | N/A    | 95                    | N/A        | N/A                    | N/A          |
|                 |           | Min Dose  | 29.1              | 34.7   | 22.5                  | 25.9       | -22.7                  | -25.4        |
|                 |           | Max Dose  | 30.5              | 36.7   | 31.9                  | 38.7       | 4.6                    | 5.4          |
|                 | PTV60     | %V100     | 95.5              | N/A    | 95                    | N/A        | N/A                    | N/A          |
|                 |           | Min Dose  | 39.6              | 47.4   | 36.6                  | 43.3       | -7.6                   | -8.7         |
|                 |           | Max Dose  | 40.2              | 48.2   | 40.9                  | 49.3       | 1.7                    | 2.2          |
|                 | Bilateral NSC | Mean Dose | 36.8              | 43.6   | 34.3                  | 40.2       | -6.8                   | -7.8         |
|                 |           | Min Dose  | 27.1              | 30.8   | 16.4                  | 17.7       | -39.5                  | -42.4        |
|                 |           | Max Dose  | 40.7              | 49     | 42.7                  | 51.8       | 69                     | 5.7          |
|                 | Bilateral Hippocampus | Mean Dose | 36.2              | 69     | 29.6                  | 51.5       | -18.2                  | -25.4        |
|                 |           | Min Dose  | 33.5              | 61.6   | 15                    | 20.6       | -55.2                  | -66.5        |
|                 |           | Max Dose  | 40.4              | 81.2   | 39.2                  | 77.6       | -3                     | -4.4         |
|                 | Bilateral Limbic | Mean Dose | 34.5              | 64.3   | 30                    | 52.5       | -13                    | -18.4        |
|                 |           | Min Dose  | 16.1              | 22.6   | 8.3                   | 10         | -48.4                  | -55.7        |
|                 |           | Max Dose  | 40.7              | 82.1   | 42.3                  | 87         | 3.9                    | 6            |
the SPA plan despite a lower mean physical dose and BED, evidence of greater dose inhomogeneity within the study OAR for the SPA plans (Table 3A,3B,3C,3D,3E).

Integral dose (J) delivered to the uninvolved brain was reduced in the SPA plans as compared to the STD plans by a mean of 7.6% (range -19.3% to +0.3%). The greatest reduction in integral dose was noted in the high grade glioma SPA plans (19.3% reduction), the only treatment plan type in which integral dose was increased with sparing techniques was WVRT (0.3% increase in SPA plan versus STD plan) only treatment plan type in which integral dose was increased with sparing techniques was WVRT (0.3% increase in SPA plan versus STD plan).

Discussion
Cranial radiotherapy plays an important role in the treatment of a number of primary pediatric intracranial tumors [1-5]. In the case of CNS germinoma and brainstem glioma, cranial radiotherapy is a standard primary treatment modality, and studies in the setting of CNS germinoma which have attempted to exclude radiotherapy as a component of treatment have shown significantly inferior results [6-8,10].

Unfortunately, the use of cranial radiotherapy in children results in a number of adverse late sequelae include cognitive dysfunction, endocrinologic dysfunction, and vascular damage [13-15]. The cognitive dysfunction can be profound, with St. Jude Children's Hospital and others finding a direct correlation between the dose administered and a decline in overall IQ [14,23-26]. In the St. Jude study, the factors that seem to correlate most strongly were younger age at time of treatment, longer time interval since treatment, female sex, presence of hydrocephalus, higher volume of supratentorial brain irradiated, and higher radiation dose to the supratentorial brain [26]. They also found that irradiation of the supratentorial compartment and temporal lobes resulted in significant declines in IQ regardless of the dose exposure, with each Gy of exposure having a similar impact on declines in IQ [23]. The cognitive deficits seen after treatment are predominantly the inability to develop new skills and process new information, rather than loss of previously acquired function and memories [14].

Changes in fractional anisotropy (FA) on diffusion tensor imaging (DTI) MRI provide evidence of damage to white matter pathways, and these changes can be seen in pediatric patients who have been treated with radiotherapy for medulloblastoma and surgical resection for cerebellar astrocytomas, with one recent study showing a mean reduction in FA of 16.5%in treated patients versus controls [27-29]. These reductions in FA were found to correlate with a younger age at the time of treatment and declines in school performance [28]. Rueckriegel et al. found that supratentorial changes in FA were more prominent in patients treated with radiotherapy and surgical resection than with surgery alone, although the distribution of deficits was similar. Interestingly, the location of most of the changes as identified in (Figure 1) of their paper lie within the hippocampus, limbic circuit, or neural stem cell compartment [29].

Johannesen and colleagues have shown in a retrospective review of MRI studies from a group of adult patients previously treated with cranial radiotherapy (median dose 54 Gy) that doses of 29.2 Gy or above are associated with grade 3 white matter changes on MRI T2 and FLAIR sequences and worse neurocognitive outcomes and patient-reported quality of life, while doses in the range of 12.5-27.5 Gy delivered to the contralateral hemisphere were not associated with such changes [30]. This study, although performed in adult patients, is consistent with the findings from the group at St. Jude's which found that the percent volume of pediatric supratentorial brain irradiated to varying dose levels (0-20Gy, 20-40Gy, 40-65Gy) correlated with IQ level after cranial irradiation [24].

Since the total dose delivered to the brain in the treatment of primary pediatric brain tumors exceeds this threshold of 20-27.5Gy (Table 1), it would follow that reduction of dose to non-target regions of the brain in children should improve imaging and clinical outcomes [29-30].

Several investigators have demonstrated the feasibility of sparing NSC, limbic circuit, and/ or hippocampus in adults during the administration of partial brain radiotherapy (PBRT) for glioma and whole brain radiotherapy (WBRT)[19,21,32-34]. The Radiation Therapy Oncology Group (RTOG) is currently accruing patients to a phase II study (RTOG 0933) which aims to demonstrate the feasibility of sparing the hippocampus during the administration of whole brain radiotherapy. This study will incorporate baseline and follow up neurocognitive testing to assess the impact of hippocampal sparing on memory and other cognitive domains after treatment [RTOG.org].

Cranial irradiation also produces damage to the hypothalamic-pituitary axis, particularly in children at doses as low as 18Gy [13,35-38]. This study was not designed to specifically evaluate dosimetric sparing of the pituitary-hypothalamic axis, but we are able in all plans (STA and SPA) to meet our planning objectives for the hypothalamic-pituitary axis (Table 2). Thus, efforts directed toward dosimetrically sparing the study OAR did not compromise dosage to the pituitary-hypothalamic axis.

In the current study, we have demonstrated the feasibility of sparing the limbic circuit, hippocampus, and neural stem cell compartment, with mean physical dose and BED to each structure reduced 44% and 47.9%, respectively. In most cases we selected these structures bilaterally for sparing, but in the hemispheric glioma and skull base sarcoma plans we elected to spare these structures contralaterally as they could not be spared ipsilaterally due to the proximity of the PTV to the ipsilateral study OAR. We anticipate that these patients (those with the study OAR spared contralaterally only) will still derive a late cognitive benefit based on the available literature detailing the cognitive outcomes for
Figure 1. Low grade hemispheric glioma standard (STD, left) and sparing (SPA, right) isodose distributions. Key: thin teal 30Gy IDL (isodose line), thin dark blue 40Gy IDL, thin yellow 50Gy IDL, thin red 54Gy, thick purple bilateral NSC (neural stem cell compartment), thick lime green bilateral HIP (hippocampus), thick blue bilateral LC (limbic circuit), thick red PTV (planning treatment volume)
Figure 2. CNS germinoma involved field radiotherapy (IFRT) standard (STD, left) and sparing (SPA, right) isodose distributions. Key: thin teal 10Gy IDL (isodose line), thin dark blue 20Gy IDL, thin yellow 30Gy IDL, thin red 40Gy, thick purple bilateral NSC (neural stem cell compartment), thick lime green bilateral HIP (hippocampus), thick blue bilateral LC (limbic circuit), thick red PTV (planning treatment volume)
patients who have undergone surgical temporal lobectomy for treatment of tumor or intractable epilepsy [40-42]. Such patients rarely have persistent cognitive deficits provided that the resected medial temporal lobe structures are diseased and the remaining medial temporal lobe structures are normal, suggesting that the remaining structures can compensate for any transient deficits sustained from the surgical procedure [40-42].

We believe that damage to the critical study OAR in this study (LC, HIP, NSC) is the principal cause of late neurocognitive deficits in both adult and pediatric patients, and our sparing is based around this assumption. However, others have suggested that low dose radiation exposure to the whole brain produces (or at least contributes) to these late adverse effects [43-44]. This theory suggests that it is reduction of the integral/overall dose to the brain which will ultimately provide cognitive protection. Investigators from Brazil has demonstrated the ability of IMRT to reduce the high dose regions and integral dose to the brain during the delivery of WVRT for primary CNS germinoma [31]. We similarly found in this study that the use of Tomotherapy IMRT reduced the integral dose delivered to the uninvolved brain by a mean of 7.6%, with all plan types showing benefit except for the WVRT plans, in which sparing techniques increased integral dose by 0.3%. This reduction in integral dose to uninvolved brain might also reduce the incidence of secondary tumor induction in this at-risk patient population.

Recently concern has been expressed over the use of intensity-modulated radiotherapy (IMRT) in the setting or cranial irradiation, since more total monitor units (MU) are required to deliver a given dose with this treatment modality, resulting in greater integral dose being delivered to the patient [45-47]. This finding has been shown in some but not all dosimetric studies comparing IMRT to either conventional/2-D or 3-D conformal treatment planning, with some studies showing a higher ID delivered to the brain and other showing a lower ID [45-51]. Reduction of ID should, in theory, reduce the risk of late second malignancies and cognitive dysfunction, although this has not been conclusively proven [45-46].

IMRT also produces more inhomogeneous dose distributions than conventional or 3-D conformal radiotherapy plans, with greater hot and cold spots (areas receiving more and less than prescription dose, respectively). This issue was noted in our treatment planning study, in which hot spots within the PTVs were in some cases >120% of prescription dose. While ideally these hot spots will be positioned within the tumor rather than within normal tissue, there is some concern that hot spots in normal brain may increase the risk for late adverse effects such as radionecrosis. For example, the commonly accepted TDS/5 (the dose which will result in a 5% risk of adverse events at 5 years in a given tissue) for normal partial brain is 60Gy [52]. Therefore, in the context of IMRT treatment planning for intracranial malignancies it would be prudent to minimize hot spots to the extent possible, and if possible to have them located within tumor rather than normal brain.

Also, since most recurrences of glioma (high and low grade) occur at or within 2cm of the original site of disease after resection and/or radiotherapy, we do not believe that our cognitive sparing approach will increase the risk of relapse for these patients, as we did not compromise definition or dosimetric coverage of our treatment targets (Tables 1 and e1) [56].

Another important approach to normal tissue sparing in the setting of cranial radiotherapy for pediatric brain tumors is the use of proton therapy [57-69]. Investigators at several institutions have performed dosimetric studies comparing the dose delivered to normal tissues with proton therapy as compared to IMRT and/or conventional radiotherapy, and have consistently shown a reduction in dose to critical normal tissues favoring proton therapy [57,60,64-65]. Proton therapy has also been shown to reduce the integral dose to the body when compared with IMRT, and this reduction in integral dose is expected to result in a lower rate of secondary tumor induction after treatment [66-69]. This is a particularly important issue in children, and the use of IMRT (including helical tomotherapy) in this context, with its associated higher total body integral dose (due to a higher number of monitor units [MU] and higher leakage dose required to deliver a given dose of therapeutic radiation), should be approached with caution [67-68]. Importantly, no prospective randomized trials have been performed comparing proton therapy versus IMRT clinical outcomes in terms of either tumor control or late effects in the setting of adult or pediatric primary tumor treatment.

We believe that the cognitive sparing approach detailed in this study and our previous studies should be implemented in the setting of a prospective clinical trial [19,21,39]. Formal neurocognitive data should be collected at baseline and following treatment to assess the functional outcome for these patients, and these results should be compared with those of either a control group treated prospectively without this approach or a historical control group with adequate follow up and neurocognitive data outcomes. Without such data, it will not be possible to properly assess the relative benefits of our approach.

**Conclusions**

It is dosimetrically possible to reduce physical dose and implicitly BED to the limbic circuit, hippocampus, and neural stem cell compartment during the administration of partial brain radiotherapy for the treatment of multiple types of pediatric primary intracranial tumors. Such treatment does not compromise dosimetric coverage of the treatment target or compromise dosimetric sparing of other critical normal structures including the pituitary-hypothalamic axis. Our cognitive sparing approach reduces integral dose to normal when compared to
standard approaches in most cases, and should reduce the late adverse cognitive effects of radiotherapy in children, but needs to be studied in the context of a prospective clinical trial with formal evaluation of neurocognitive outcomes.

Competing interests
The authors declare that they have no competing interests.

Author details
1Rohit Godbole, B.S., Rush Medical College, 1653 West Congress Parkway, Chicago, IL. 60612, (312) 942-5000
2Aidnag Diaz, M.D., Rush University Medical Center, Department of Radiation Oncology, 500 S. Paulina, Chicago, IL. 60612, (312) 942-5751, faxe (312) 942-2339
3Arnold Herskovic, M.D., Rush University Medical Center, Department of Radiation Oncology, 500 S. Paulina, Chicago, IL. 60612, (312) 942-5751, faxe (312) 942-2339
4Julius Turian, Ph.D., Rush University Medical Center, Department of Radiation Oncology, 500 S. Paulina, Chicago, IL. 60612, (312) 942-5751, faxe (312) 942-2339

Authors contributions
Dr. James Marsh designed this study, performed and/or reviewed all treatment plans, and prepared and submitted this manuscript. Rohit Godbole assisted in the preparation of treatment plans and manuscript preparation.
Dr. Aidnag Diaz assisted in study design, plan review, and manuscript review.
Dr. Arnold Herskovic assisted in study design and manuscript review.
Dr. Julius Turian assisted in study design, plan preparation, and manuscript review.

Acknowledgments & Funding
We would like to thank Joseph Smart for his help in the preparation of the treatment plans utilized for this study.
No extra-departmental funding supported this study.

Article History
Editor: Giovanni P. Frezza, University of Bologna, Italy
EIC: Prof. G. J. Peters, VU University Medical Center, Netherlands.
Received: 20 December 2011
Revised: 10 January 2012
Accepted: 12 January 2012
Published: 14 February 2012

References
1. Baumann G, Fisher B, Schild S, et al. Ch.25: Meningioma, ependymoma, and other adult brain tumors. In: Clinical radiation oncology. 2nd ed. Philadelphia: Churchill Livingstone. 2007. p. 548-549, 554-556, 560-561.
2. Jakacki Ri. Treatment strategies for high-risk medulloblastoma and supratentorial primitive neuroectodermal tumors. Review of the literature. J Neurosurg 2005; 102 (Suppl.): 44-52.
3. Merchant TE, Wang MH, Haida T, et al. Medulloblastoma: Long-term results for patients treated with definitive radiation therapy during the computed tomography era. Int J Radiat Oncol Biol 1996; 36: 29-35.
4. Halperin EC. Impact of radiation therapy technique upon the outcome of treatment for medulloblastoma. Int J Radiat Oncol Biol 1996; 36: 233-239.
5. Berger C, Thiesse P, Lellouch-Tubiana A, et al. Chorioid plexus carcinomas in childhood: clinical features and prognostic factors. Neurosurgery 1998; 42: 470-475.
6. Haas-Kogan DA, Missett BT, Wara WM, et al. Radiation therapy for intracranial germ cell tumors. Int J Radiat Oncol Biol Phys 2003; 56 (2):511-518.
7. Matsutani M. Pineal germ cell tumors. Prog Neurol Surg 2009; 23:76-85.
8. Shim KW, Kim TG, Suh CO, et al. Treatment failure in intracranial primary germinomas. Childs Nerv Syst 2007; 23(10):1155-1161.
9. Sievert AJ, Fisher MJ. Pediatric low-grade gliomas. J Child Neurol 2009; 24(11):1397-1408.
10. Leblond P, Vinchon M, Bernier-Chastagner V, et al. Diffuse intrinsic brainstem glioma in children: current treatment and future directions. Arch Pediatr 2010; 17(2):159-165.
11. Duffner PK, Horowitz ME, Krischer JP, et al. Postoperative chemotherapy and delayed radiation in children less than three years of age with malignant brain tumors. NEJM 1993; 328:1725-1731.
12. Rutkowski S, Bode U, Deinlein F, et al. Treatment of early childhood medulloblastoma by postoperative chemotherapy alone. NEJM 2005; 352:978-986.
13. Nandagopal R, Laverdiere c, Mulrooney D, et al. Endocrine late effects of childhood cancer therapy: a report from the Children’s Oncology Group. Horm Res 2008; 69:65-74.
14. Merchant TE, Kiehna EN, Li C, et al. Modeling radiation dosimetry to predict cognitive outcomes in pediatric patients with CNS embryonal tumors including medulloblastoma. Int J Radiat Oncol Biol Phys 2006; 65 (1):210-221.
15. Kondoh T, Morishita A, Kamei M, et al. Moyamoya syndrome after prophylactic cranial irradiation for acute lymphocytic leukemia. Pediatr Neurosurg 2003; 39(5):264-269.

16. Lautin A. The Limbic Brain. New York, Kluwer Academic/ Plenum Publisher, 2001.

17. Barani IJ, Benedict SH, Lin PS. Neural stem cells: Implications for the conventional radiotherapy of central nervous system malignancies. Int J Radiat Oncol Biol Phys 2007; 68:324-333.

18. Marsh J, Gielda B, Herskovic A, et al. Cognitive sparing during the administration of whole brain adiotherapy and prophylactic cranial irradiation: current concepts and approaches. J Oncol 2010 [Epub ahead of print]

19. Marsh J, Godbole R, Herskovic A, et al. Sparing of the neural stem cell compartment during whole-brain radiation therapy: a dosimetric study using helical tomotherapy. Int J Radiat Oncol Biol Phys 2010; 78(3):946-954.

20. Marsh J, Gielda B, Herskovic A, et al. Sparing of the hippocampus and limbic circuit during whole brain radiation therapy: a dosimetric study using helical tomotherapy. J Med Imaging Radiat Oncol 2010; 54(4):375-382.

21. Marsh J, Godbole R, Diaz A, et al. Sparing of the hippocampus, limbic circuit, and neural stem cell compartment during partial brain radiotherapy for glioma: a dosimetric feasibility study. [submitted for publication]

22. Hall EJ, Giacca AJ (eds.) Ch.18 Dose-response relationships for model normal tissues. From Radiobiology for the radiologist 6th edition. Lippincott Williams & Wilkins 2006.

23. Palmer SL, Goloubeva O, Reddick WE, et al. Patterns of intellectual development among survivors of pediatric medulloblastoma: a longitudinal analysis. J Clin Oncol 2001; 19(8):2302-2308.

24. Merchant TE, Kiehna EN, Li C, et al. Radiation dosimetry predicts IQ after conformal radiation therapy in pediatric patients with localized ependymoma. Int J Radiat Oncol Biol Phys 2005; 63(5):1546-1554.

25. Merchant TE, Mulhern RK, Krasin MJ, et al. Preliminary results from a phase II trial of conformal radiation therapy and evaluation of radiation-related CNS effects for pediatric patients with localized ependymoma. J Clin Oncol 2004; 22(15):3156-3162.

26. Mulhern RK, Merchant TE, Gajjar A, et al. Late neurocognitive sequelae in survivors of brain tumours in childhood. Lancet Oncol 2004; 5(7):399-408.

27. Welzel T, Niethammer A, Mende U, et al. Diffusion tensor imaging screening of radiation-induced changes in the white matter after prophylactic cranial irradiation of patients with small cell lung cancer: first reports of a prospective study. Am J Neurorad 2008; 29:379-383.

28. Khong P-L, Kwong DL, Chan GC, et al. Diffusion-tensor imaging for the detection and quantification of treatment-induced white matter injury in children with medulloblastoma: a pilot study. Am J Neurorad 2003; 24:734-740.

29. Rueckriegel SM, Driever PH, Blankenburg F, et al. Differences in supratentorial damage of white matter in pediatric survivors of posterior fossa tumors with and without adjuvant treatment as detected by magnetic resonance diffusion tensor imaging. Int J Radiat Oncol Biol Phys 2010; 76(3):859-866.

30. Johannesen T, Lien H, Hole K, et al. Radiological and clinical assessment of long-term brain tumour survivors after radiotherapy. Radiother Oncol 2003; 69:169-176.

31. Chen MW, Santos AS, Sakuraba RK, et al. Intensity-modulated and 3-D conformal radiotherapy for whole-ventricular irradiation as compared with conventional whole-brain irradiation in the management of localized central nervous system germ cell tumors. Int J Radiat Oncol Biol Phys 2010; 76(2):606-614.

32. Barani I, Cuttino L, Benedict S, et al. Neural stem cell-preserving external-beam radiotherapy of central nervous system malignancies. Int J Radiat Oncol Biol Phys. 2007; 68(4):978-985.

33. Gutierrez AN, Westerly DC, Tome’WA, et al. Whole brain radiotherapy with hippocampal avoidance and simultaneously integrated brain metastases: a planning study. Int J Radiat Oncol Biol Phys 2007; 69:589-597.

34. Hsu F, Carolan H, Nichol A, et al. Whole brain radiotherapy with hippocampal avoidance and simultaneous integrated boost for 1-3 brain metastases: a feasibility study using volumetric modulated arc therapy. Int J Radiat Oncol Biol Phys 2009 (Epub ahead of print).

35. Darzy KH. Radiation-induced hypopituitarism after cancer therapy: who, how and when to test. Natl Clin Pract Endocrinol Metab 2009; 5(2):88-99.

36. Toogood AA. Endocrine consequences of brain irradiation. Growth Horm IGF Res 2004; 14(Suppl A):S118-124.

37. Darzy KH, Shalet SM. Hypopituitarism following radiotherapy. Pituitary 2009; 12(1):40-50.

38. Darzy KH, Shalet SM. Hypopituitarism as a consequence of brain tumours and radiotherapy. Pituitary 2005; 8(3-4):203-211.

39. Marsh J, Garg S, Wendt J, et al. Intracranial metastatic disease rarely involves the pituitary: retrospective analysis of 935 metastases in 155 patients and review of the literature. Pituitary 2010; 13(3):260-265.

40. Di Gennaro G, Grammaldo L, Quario P, et al. Severe amnesia following bilateral medial temporal lobe damage occurring on two distinct occasions. Neurol Sci 2006; 27(2):129-133.

41. Giovagnoli AR, Casazza M, Ciceri E, et al. Preserved memory in temporal lobe epilepsy patients after surgery for low-grade tumour. A pilot study. Neurol Sci 2007; 28(5):251-258.

42. Chelune G, Najm I. Ch. 53 Risk factors associated with post-surgical decrements in memory, from Epilepsy Surgery. 2nd Edition. Eds. Luders H, Comair Y. Lippincott Williams & Wilkins 2001.
43. Hoffman K, Yock T. Radiation therapy for pediatric central nervous system tumors. J Child Neurol 2009; 24(11):1387-1396.

44. Kirsch D, Tarbell N. Conformal radiation therapy for childhood CNS tumors. Oncologist 2004; 9(4): 442-450.

45. Hall EJ, Wuu CS. Radiation-induced second cancers: the impact of 3D-CRT and IMRT. Int J Radiat Oncol Biol Phys 2003; 56(1): 83-88.

46. Ruben JD, Davis S, Evans C, et al. The effect of intensity-modulated radiotherapy on radiation-induced second malignancies. Int J Radiat Oncol Biol Phys 2008; 70(5):1530-1536.

47. Zach L, Stall B, Ning H, et al. A dosimetric comparison of four different treatment planning methods for high grade glioma. Radiat Oncod 2009; 4:45.

48. Shi C, Penagaricano J, Papanikolaou N. Comparison of IMRT treatment plans between linac and helical tomotherapy based on integral dose and inhomogeneity index. Med Dosim 2008; 33(3):215-221.

49. Raggi E, Mosleh-Shirazi MA, saran FH. An evaluation of conformal and intensity-modulated radiotherapy in whole ventricular radiotherapy for localized primary intracranial germinomas. Clin Oncol (R Coll Radiol) 2008; 20(3):253-260.

50. Chen MJ, Santos Ada S, Sakuraba RK, et al. Intensity-modulated and 3D-conformal radiotherapy for whole-ventricular irradiation as compared with conventional whole-brain irradiation in the management of localized central nervous system germ cell tumors. Int J Radiat Oncol Biol Phys 2010; 76(2):608-614.

51. MacDonald SM, Ahmad S, Kachris S, et al. Intensity modulated radiation therapy versus three-dimensional conformal radiation therapy for the treatment of high grade glioma: a dosimetric comparison. J Appl Clin Med Phys 2007; 8(2):47-60.

52. Emami B, Lyman J, Brown A, et al. Tolerance of normal tissue to therapeutic irradiation. Int J Radiat Oncol Biol Phys. 1991; 21(1):109-22.

53. Weinstein J, Ayyanar K, Watral M. Secondary neoplasms following treatment for brain tumors. Cancer Treat Res 2009; 150:239-273.

54. Von der Weid N. Adult life after surviving lymphoma in childhood. Support Care Cancer 2008; 16(4) 339-345.

55. Strojan P, Popovic’ M, Jereb B. Secondary intracranial meningiomas after high-dose cranial irradiation: report of five cases and review of the literature. Int J Radiat Oncol Biol Phys 2000; 48(1):65-73.

56. Chan JL, Lee SW, Fraass BA, et al. Survival and failure patterns of high-grade gliomas after three-dimensional conformal radiotherapy. J Clin Oncol 2002; 20:1635-1642.

57. St. Clair WH, Adams JA, Bues M, et al. Advantages of protons compared to conventional X-ray or IMRT in the treatment of a pediatric patient with medulloblastoma. Int J Radiat Oncol Biol Phys 2004; 58:727-734.

58. Chin YL, Yock T, Butler W, et al. Reduction of cochlear dose using proton boost for pediatric medulloblastoma [abstract]. Proceedings of the 11th International Symposium on Pediatric Neuro-oncology 2004.

59. Yock Ti, Tarbell NJ. Technology insight: proton beam radiotherapy for treatment in pediatric brain tumors. Nature Clinical Practice in Oncology 2004; 1(2): 97-103.

60. Hug EB, Muenter MW, Archambeau JO, et al. Conformal proton radiation therapy for pediatric low-grade astrocytomas. Strahlenther Onkol 2002; 178: 10-17.

61. Noel G, Habrand JL, Helfres S, et al. Proton beam therapy in the management of central nervous system tumors in childhood: the preliminary experience of the Centre de Protontherapie d’Orsay. Med Pediatr Oncol 2003; 40:309-315.

62. McAllister B, Archambeau JO, Nguyen MC, et al. Proton therapy for pediatric cranial tumors: preliminary report on treatment and disease-related morbidities. Int J Radiat Oncol Biol Phys 1997; 39: 455-160.

63. MacDonald SM, Yock Ti. Proton beam therapy following resection for childhood ependymoma. Childs Nerv Syst 2010; 26:285-291.

64. MacDonald SM, Safai S, Trofimov A, et al. Proton radiotherapy for childhood ependymoma: initial clinical outcomes and dose comparisons. Int J Radiat Oncol Biol Phys 2008; 71(4):979-986.

65. Palm A, Johansson K. A review of the impact of photon and proton external beam radiotherapy treatment modalities on the dose distribution in field and out-of-field; implications for the long-term, morbidity of cancer survivors. Acta Oncol 2007; 47:462-473.

66. Mu X, Bjork-Eriksson T, Nill S, et al. Does electron and proton therapy reduce the risk of radiation induced cancer after spinal irradiation for childhood medulloblastoma? A comparative treatment planning study. Acta Oncol 2005; 44:554-562.

67. Hall EJ, Phil D. Intensity-modulated radiation therapy, protons, and the risk of second cancers. Int J Radiat Oncol Biol Phys 2006; 65(1):1-7.

68. Schneider U, Lomax A, Pemler P, et al. The impact of IMRT and proton radiotherapy on secondary cancer incidence. Strahlenther Onkol 2006; 11647-652.

69. Yoon M, Ahn SH, Kim J, et al. Radiation-induced cancers from modern radiotherapy techniques: intensity-modulated radiotherapy versus proton therapy. Int J Radiat Oncol Biol Phys 2010; 77(5):1477-1485.